OraSure Technologies (NASDAQ:OSUR) released its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02, Briefing.com reports. The business had revenue of $45.90 million during the quarter, compared to analysts’ expectations of $44.50 million. OraSure Technologies had a return on equity of 5.85% and a net margin of 8.38%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.09 EPS. OraSure Technologies updated its FY 2018 guidance to $0.09-0.11 EPS and its Q4 guidance to $0.09-0.11 EPS.
OraSure Technologies stock traded up $0.16 during midday trading on Friday, reaching $13.35. 20,968 shares of the stock traded hands, compared to its average volume of 533,192. OraSure Technologies has a 12-month low of $12.50 and a 12-month high of $22.22. The stock has a market capitalization of $883.96 million, a price-to-earnings ratio of 26.90, a price-to-earnings-growth ratio of 3.40 and a beta of 1.52.
In related news, Director Charles W. Patrick sold 8,000 shares of the firm’s stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $16.29, for a total transaction of $130,320.00. Following the completion of the transaction, the director now directly owns 54,298 shares in the company, valued at approximately $884,514.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.90% of the company’s stock.
A number of equities analysts recently commented on OSUR shares. TheStreet upgraded OraSure Technologies from a “c+” rating to a “b” rating in a report on Thursday, August 9th. ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a report on Tuesday. Stephens cut OraSure Technologies from an “overweight” rating to an “equal weight” rating in a report on Monday, July 16th. Zacks Investment Research cut OraSure Technologies from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Finally, Raymond James restated a “mkt perform” rating on shares of OraSure Technologies in a report on Tuesday, October 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. OraSure Technologies presently has a consensus rating of “Hold” and an average price target of $20.50.
TRADEMARK VIOLATION WARNING: This report was originally published by WKRB News and is owned by of WKRB News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.wkrb13.com/2018/11/09/orasure-technologies-osur-releases-earnings-results-beats-estimates-by-0-02-eps.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Further Reading: Diversification For Individual Investors
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.